Molecular and clinicopathologic features of gliomas harboring NTRK fusions

Fusions involving neurotrophic tyrosine receptor kinase (NTRK) genes are detected in ≤2% of gliomas and can promote gliomagenesis. The remarkable therapeutic efficacy of TRK inhibitors, which are among the first Food and Drug Administration-approved targeted therapies for NTRK-fused gliomas, has gen...

Descripción completa

Detalles Bibliográficos
Autores principales: Torre, Matthew, Vasudevaraja, Varshini, Serrano, Jonathan, DeLorenzo, Michael, Malinowski, Seth, Blandin, Anne-Florence, Pages, Melanie, Ligon, Azra H., Dong, Fei, Meredith, David M., Nasrallah, MacLean P., Horbinski, Craig, Dahiya, Sonika, Ligon, Keith L., Santi, Mariarita, Ramkissoon, Shakti H., Filbin, Mariella G., Snuderl, Matija, Alexandrescu, Sanda
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7362646/
https://www.ncbi.nlm.nih.gov/pubmed/32665022
http://dx.doi.org/10.1186/s40478-020-00980-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7362646/
https://www.ncbi.nlm.nih.gov/pubmed/32665022
http://dx.doi.org/10.1186/s40478-020-00980-z

Ejemplares similares